Acrivon Therapeutics
Clinical-stage precision oncology company developing small-molecule therapeutics guided by a proteomics-driven patient selection platform (AP3). Uses phosphoproteomics and quantitative tissue imaging to generate drug-specific companion diagnostics for biomarker-driven clinical development, and advances a pipeline focused on DNA damage response and cell-cycle kinase inhibitors.
Industries
Nr. of Employees
medium (51-250)
Acrivon Therapeutics
Patents
Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor
US-12433888-B1
View Details
Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor
US-12433888-B1
View DetailsProducts
Clinical-stage CHK1/CHK2 inhibitor (licensed clinical asset)
A clinically advanced checkpoint kinase 1/2 inhibitor in Phase 2 development, licensed for worldwide development to treat DDR-driven solid tumors; developed with a companion diagnostic for patient selection.
Clinical-stage WEE1/PKMYT1 inhibitor (internal candidate)
Internally developed selective dual WEE1/PKMYT1 inhibitor advanced as a clinical candidate using phosphoproteomics-guided design and biological SAR.
Preclinical CDK11 inhibitor program (IND-enabling)
Preclinical small-molecule program targeting CDK11 advanced through IND-enabling studies informed by proteomics-driven target profiling.
Clinical-stage CHK1/CHK2 inhibitor (licensed clinical asset)
A clinically advanced checkpoint kinase 1/2 inhibitor in Phase 2 development, licensed for worldwide development to treat DDR-driven solid tumors; developed with a companion diagnostic for patient selection.
Clinical-stage WEE1/PKMYT1 inhibitor (internal candidate)
Internally developed selective dual WEE1/PKMYT1 inhibitor advanced as a clinical candidate using phosphoproteomics-guided design and biological SAR.
Preclinical CDK11 inhibitor program (IND-enabling)
Preclinical small-molecule program targeting CDK11 advanced through IND-enabling studies informed by proteomics-driven target profiling.
Services
Collaborative development and prospective validation of quantitative tissue-imaging companion diagnostics to enable biomarker-stratified clinical trials.
Phosphoproteomic profiling and bioinformatic analysis to identify drug-sensitive tumor types, resistance mechanisms, and rational combination strategies.
Collaborative development and prospective validation of quantitative tissue-imaging companion diagnostics to enable biomarker-stratified clinical trials.
Phosphoproteomic profiling and bioinformatic analysis to identify drug-sensitive tumor types, resistance mechanisms, and rational combination strategies.
Expertise Areas
- Precision oncology
- Phosphoproteomics biomarker discovery
- Companion diagnostic development and validation
- Biomarker-driven clinical trial design
Key Technologies
- Phosphoproteomics
- High-resolution mass spectrometry
- Multiplex immunofluorescence / quantitative tissue imaging
- AI-driven kinase–substrate prediction models
News & Updates
Announcement of an exclusive worldwide license to develop a clinically advanced CHK1/2 inhibitor (prexasertib) to advance a biomarker-driven clinical program.
FDA clearance for an innovative Phase 2 trial to treat ovarian, endometrial and urothelial cancer patients based on predicted sensitivity to the licensed CHK1/2 inhibitor.
Announcement of an oversubscribed $100 million Series B financing to advance the AP3 precision proteomics platform and clinical oncology pipeline.
Exclusive worldwide license to develop and commercialize a clinically advanced DNA damage response kinase inhibitor (prexasertib).
$100 million Series B financing to fund the proteomics platform and clinical pipeline.
Announcement of an exclusive worldwide license to develop a clinically advanced CHK1/2 inhibitor (prexasertib) to advance a biomarker-driven clinical program.
FDA clearance for an innovative Phase 2 trial to treat ovarian, endometrial and urothelial cancer patients based on predicted sensitivity to the licensed CHK1/2 inhibitor.
Announcement of an oversubscribed $100 million Series B financing to advance the AP3 precision proteomics platform and clinical oncology pipeline.
Exclusive worldwide license to develop and commercialize a clinically advanced DNA damage response kinase inhibitor (prexasertib).
$100 million Series B financing to fund the proteomics platform and clinical pipeline.